From SARS-CoV to SARS-CoV-2 : safety and broad-spectrum are important for coronavirus vaccine development
Copyright © 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved..
The global pandemic of COVID-19 caused by SARS-CoV-2 (also known as 2019-nCoV and HCoV-19) has posed serious threats to public health and economic stability worldwide, thus calling for development of vaccines against SARS-CoV-2 and other emerging and reemerging coronaviruses. Since SARS-CoV-2 and SARS-CoV have high similarity of their genomic sequences and share the same cellular receptor (ACE2), it is essential to learn the lessons and experiences from the development of SARS-CoV vaccines for the development of SARS-CoV-2 vaccines. In this review, we summarized the current knowledge on the advantages and disadvantages of the SARS-CoV vaccine candidates and prospected the strategies for the development of safe, effective and broad-spectrum coronavirus vaccines for prevention of infection by currently circulating SARS-CoV-2 and other emerging and reemerging coronaviruses that may cause future epidemics or pandemics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Microbes and infection - 22(2020), 6-7 vom: 19. Juli, Seite 245-253 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ma, Cuiqing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2019-nCoV |
|---|
| Anmerkungen: |
Date Completed 14.08.2020 Date Revised 28.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.micinf.2020.05.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310202116 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310202116 | ||
| 003 | DE-627 | ||
| 005 | 20240328235059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.micinf.2020.05.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM310202116 | ||
| 035 | |a (NLM)32437926 | ||
| 035 | |a (PII)S1286-4579(20)30082-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ma, Cuiqing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a From SARS-CoV to SARS-CoV-2 |b safety and broad-spectrum are important for coronavirus vaccine development |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.08.2020 | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a The global pandemic of COVID-19 caused by SARS-CoV-2 (also known as 2019-nCoV and HCoV-19) has posed serious threats to public health and economic stability worldwide, thus calling for development of vaccines against SARS-CoV-2 and other emerging and reemerging coronaviruses. Since SARS-CoV-2 and SARS-CoV have high similarity of their genomic sequences and share the same cellular receptor (ACE2), it is essential to learn the lessons and experiences from the development of SARS-CoV vaccines for the development of SARS-CoV-2 vaccines. In this review, we summarized the current knowledge on the advantages and disadvantages of the SARS-CoV vaccine candidates and prospected the strategies for the development of safe, effective and broad-spectrum coronavirus vaccines for prevention of infection by currently circulating SARS-CoV-2 and other emerging and reemerging coronaviruses that may cause future epidemics or pandemics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a 2019-nCoV | |
| 650 | 4 | |a Cross-protection | |
| 650 | 4 | |a HCoV-19 | |
| 650 | 4 | |a SARS-CoV | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Vaccine | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Inactivated |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Su, Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jiachao |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Lanying |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Shibo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Microbes and infection |d 1999 |g 22(2020), 6-7 vom: 19. Juli, Seite 245-253 |w (DE-627)NLM105022780 |x 1769-714X |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2020 |g number:6-7 |g day:19 |g month:07 |g pages:245-253 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.micinf.2020.05.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2020 |e 6-7 |b 19 |c 07 |h 245-253 | ||